O guia definitivo sobre edição genética.
Menu
Início Aprender Notícias Perguntar ao Atlas
Explorar Tecnologias Doenças Tratamentos Ensaios Clínicos Empresas Cientistas Genes Investigação Instituições
Para além da medicina Agricultura Ética Investimento Mapa mundial
Aprender e ferramentas Comece aqui Glossário A–Z Comparar tecnologias Cronologia Listas e rankings Agentes de IA ★ Guardado API
Sobre Sobre nós Metodologia Fontes de dados Política editorial Contato Avisos legais

🧭 Vista Guiada
É novo em genética? Explicamos cada termo à medida que navega, em linguagem simples. As mesmas páginas, com a ajuda integrada.

⚡ Opinião de Especialista
Você já conhece a biologia. Apenas o conteúdo — limpo e compacto, sem explicações extras. Esta é a visualização padrão.

Idioma da interface
Modo claro

Ferramenta

Comparar tecnologias

Escolha duas ou três abordagens e veja como diferem em precisão, corte de DNA, tamanho da carga, entrega, maturidade clínica e riscos conhecidos.

Escolha duas tecnologias acima ou leia uma das comparações escritas abaixo.

Comparações escritas

As distinções que as pessoas mais frequentemente confundem, explicadas de forma clara.

Todas as tecnologias

Abrir a base de dados →
CRISPR-Cas9A protein that can be programmed with a short RNA guide to find one specific sequence in a genome and cut it. Approved Base EditingChemically converts one DNA letter into another at a chosen position, without cutting both strands of the double helix. Phase III Prime EditingWrites a new stretch of DNA sequence directly into a chosen site, using a guide that carries the replacement text with it. Phase I/II CRISPR-Cas12A family of CRISPR nucleases that cut DNA leaving staggered ends, use a different sequence requirement from Cas9, and can be smaller. Phase I/II CRISPR-Cas13Targets RNA rather than DNA, so it can silence a gene's message without touching the genome itself. Phase I Cas14 and miniature Cas systemsUnusually small CRISPR nucleases — roughly a third the size of Cas9 — discovered in archaea and bacteriophages. Discovery RNA EditingChanges letters in the RNA message rather than in the DNA, so the effect is real but temporary and the genome is untouched. Phase I/II Epigenetic EditingChanges how loudly a gene is expressed by rewriting the chemical marks on and around it, without altering a single letter of DNA sequence. Preclinical CRISPRa (gene activation)Uses a disabled CRISPR protein to switch a gene up rather than to cut it. Research tool CRISPRi (gene silencing)Parks a disabled CRISPR protein on a gene to block it from being read, turning it down without changing it. Research tool TALENsCustom-built proteins that recognise DNA letter by letter and cut — the technique CRISPR largely displaced, still in clinical use. Phase I/II Zinc Finger NucleasesThe first programmable gene-editing tool to reach patients — small, engineered proteins that grip DNA in three-letter blocks. Phase III Recombinases and integrasesEnzymes that cut and rejoin DNA at defined sites, able to insert whole genes rather than edit single letters. Preclinical TransposasesEnzymes that cut a segment of DNA out of one place and paste it into another — nature's own copy-and-paste. Phase I/II Gene Therapy (gene addition)Delivers a working copy of a gene into cells without changing the existing genome — the older approach that gene editing is often confused with. Approved RNA InterferenceUses the cell's own machinery to destroy a specific RNA message, lowering a protein's level without touching DNA. Approved Synthetic BiologyDesigning genetic parts and circuits so that cells perform new functions — the engineering discipline that gene editing serves as a tool. Phase III